Stoke Therapeutics' Mounting Losses May Actually Validate Its Platform Better Than a Profit Would

Stoke Therapeutics (NASDAQ: STOK) reports first-quarter 2026 earnings after market close on Wednesday, May 7, 2026, with analysts expecting a loss of $0.80 per share. The biotech's lead program, zorevunersen for Dravet syndrome, is advancing through a pivotal Phase 3 trial with accelerated enrollment timelines, making this report a critical checkpoint for investors tracking the company's path toward potential FDA approval. With the stock trading at $33.28 and Wall Street maintaining overwhelmingly bullish sentiment—11 Strong Buy ratings and a consensus target of $45.07—the question is whether clinical momentum and cash runway can justify the premium valuation heading into this release.

Part 1: Earnings Preview

Stoke Therapeutics is a clinical-stage biotechnology company developing antisense oligonucleotide therapies using its proprietary TANGO platform to restore protein expression in severe genetic diseases. The company's lead candidate, zorevunersen (STK-001), targets Dravet syndrome—a rare and devastating childhood epilepsy—and is currently enrolling patients in the Phase 3 EMPEROR study, with data readout expected mid-2027 to support an NDA filing in the first half of 2027.

For Q1 2026, analysts expect STOK to report a loss of $0.80 per share on revenue of approximately $6.48 million. The company most recently reported Q4 2025 results with an EPS of -$0.97, missing estimates by 29.33%. Comparing to the year-ago quarter (Q1 2025), when STOK posted a surprising profit of $1.90 per share driven by a one-time milestone payment from its Biogen collaboration, the current estimate of -$0.80 represents a -142.11% year-over-year decline—though this comparison is distorted by the non-recurring revenue event.

Three key themes define this earnings story:

Phase 3 EMPEROR Study Progress: Investors will scrutinize updates on patient enrollment and trial execution. Stoke announced in January 2026 that it expects to complete enrollment of approximately 150 patients in Q2 2026, ahead of the original timeline. Any confirmation of this accelerated pace—or news that enrollment has been completed—would be a significant catalyst. With more than 200 patients pre-screened and over 30 active sites, the company appears on track, but concrete enrollment numbers and site activation updates will be critical.

Cash Runway and Burn Rate: With a market cap of $2.0 billion but operating losses continuing, investors need clarity on how long the current cash position ($0.3 billion as of year-end 2025) will fund operations. The company's quarterly burn rate and any commentary on financing needs or partnership economics with Biogen will be closely watched. Share-based compensation running at 17% of revenue adds to dilution concerns.

Clinical Data Publication and Regulatory Momentum: The March 2026 publication of Phase 1/2a data in The New England Journal of Medicine provided third-party validation of zorevunersen's potential for disease modification, with substantial seizure reductions and cognitive improvements. Investors will look for management commentary on how this publication is influencing regulatory discussions with the FDA, particularly given the drug's Breakthrough Therapy Designation, and whether it's accelerating patient identification and enrollment.

Ahead of the release, Wall Street analysts remain overwhelmingly bullish. Wolfe Research initiated coverage in February with an Outperform rating and $40 target, while Guggenheim launched coverage with a Buy rating and $60 target—the Street high. Needham raised its target from $35 to $40 following the Q4 report, citing confidence in the EMPEROR study timeline. The consensus view is that zorevunersen represents a potentially transformative therapy for Dravet syndrome, with analysts focused on execution risk rather than questioning the scientific rationale. However, the high valuation—trading at 11.1x trailing sales and 45.4x free cash flow—leaves little room for disappointment on trial progress or cash management.

Part 2: Historical Earnings Performance

Stoke Therapeutics has delivered a volatile earnings track record over the past four quarters, with results swinging dramatically based on milestone payments rather than consistent operational performance. In Q1 2025, the company posted a stunning $1.90 per share profit, crushing estimates of -$0.37 for a +613.51% surprise—driven entirely by a large collaboration milestone from Biogen. This was followed by Q2 2025 results of -$0.40, beating the -$0.57 estimate by +29.82%, suggesting better-than-expected expense management.

The pattern reversed in the second half of 2025. Q3 2025 saw a loss of -$0.65 versus estimates of -$0.54, a -20.37% miss, as R&D spending ramped up for the Phase 3 trial. Most recently, Q4 2025 delivered a -$0.97 loss against expectations of -$0.75, missing by -29.33%—the largest percentage miss in the trailing four quarters and a sign that operating expenses are accelerating as the EMPEROR study scales up.

The trend is clear: excluding the Q1 2025 milestone windfall, STOK has missed estimates in two of the past three quarters, with losses deepening as clinical development intensifies. The company's ability to manage burn rate while maintaining aggressive enrollment timelines will be critical to watch in Q1 2026, especially given that analysts are modeling a -$0.80 loss—implying expectations for continued elevated spending.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Stoke Therapeutics typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers and management commentary.

STOK exhibits significant post-earnings volatility, with an average absolute Day 0 move of 2.79% and an average Day +1 move of 6.37%—the latter being more than double the initial reaction, suggesting that investor interpretation of management guidance and trial updates often drives larger moves than the headline numbers themselves. The average Day 0 range of 8.20% and Day +1 range of 10.42% underscore the stock's tendency for wide intraday swings around earnings events.

The most dramatic recent example came in August 2025, when the stock surged +24.98% on Day +1 following Q2 results, likely driven by positive commentary on trial progress that overshadowed the modest earnings beat. Conversely, November 2025 saw a -9.94% Day +1 decline after Q3's earnings miss, reflecting investor sensitivity to execution concerns. The March 2026 report produced a more muted +2.32% Day 0 move followed by a -3.21% Day +1 reversal, suggesting initial optimism gave way to concerns about the widening Q4 loss.

Investors should expect meaningful volatility following the Q1 2026 report, with the magnitude and direction likely hinging more on trial enrollment updates and cash runway commentary than on the quarterly loss figure itself. The historical pattern suggests that positive clinical momentum can easily override a larger-than-expected loss, while any hint of trial delays or financing needs could trigger sharp downside even if the EPS number is in line.

Part 2.2: Options Market Expected Move

The options market is pricing a 2.58% expected move through the May 15 expiration (9 days out), which is substantially below the stock's average historical Day +1 move of 6.37% and even below the average Day 0 move of 2.79%. This suggests options traders may be underpricing the potential volatility around this earnings event, particularly given STOK's history of double-digit percentage swings when clinical trial updates drive the narrative. The implied volatility of 97.06% is elevated in absolute terms but appears conservative relative to the stock's actual earnings-day behavior.

Part 3: What Analysts Are Saying

Wall Street maintains an overwhelmingly bullish stance on Stoke Therapeutics heading into the Q1 2026 report, with the consensus reflecting strong conviction in the company's clinical and commercial potential. The stock carries an average analyst recommendation of 4.77 out of 5.0—firmly in Strong Buy territory—with 11 Strong Buy ratings, 1 Moderate Buy, and just 1 Hold. Zero analysts rate the stock a Sell or Strong Sell, underscoring the Street's unified optimism around zorevunersen's prospects.

The consensus price target of $45.07 implies 35.4% upside from the current price of $33.28, with a wide range of outcomes reflected in individual targets: the high estimate of $60.00 (from Guggenheim) suggests potential for 80.3% upside if the Phase 3 trial delivers strong results and regulatory approval proceeds smoothly, while the low target of $35.00 implies only modest appreciation and reflects a more conservative view on execution risk and valuation.

Critically, analyst sentiment has remained unchanged over the past month, with ratings counts and the average recommendation holding steady at 4.77. This stability suggests the Street is in a "wait-and-see" mode ahead of the earnings report and any new trial enrollment data, rather than actively upgrading or downgrading based on recent developments. The lack of sentiment shift also indicates that the March 2026 NEJM publication and recent analyst initiations (Wolfe, Guggenheim) have been absorbed into the consensus without materially altering the overall bullish posture.

The analyst community's key focus areas align with the themes outlined earlier: confirmation of accelerated Phase 3 enrollment timelines, clarity on cash runway through the anticipated mid-2027 data readout, and any incremental regulatory feedback following the Breakthrough Therapy Designation. The high degree of buy-side conviction reflects confidence in the scientific rationale and unmet need in Dravet syndrome, but the wide target range (from $35 to $60) highlights meaningful uncertainty around commercial assumptions, competitive positioning against established anti-seizure therapies, and the ultimate probability of regulatory success.

Part 4: Technical Picture

Stoke Therapeutics enters the Q1 2026 earnings report with a mixed technical setup that has weakened notably in recent weeks. The Barchart Technical Opinion currently stands at 56% Buy, down sharply from 96% Buy a month ago and 40% Buy a week ago, signaling deteriorating near-term momentum despite the stock's strong longer-term uptrend. This rapid shift suggests technical traders are growing cautious ahead of the release, potentially reflecting profit-taking after the stock's 235% twelve-month run through early 2026.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum has stalled, with the stock consolidating after recent gains
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive but lacks strong conviction
• Long-term (100% Buy): Strong buy signal reflects the stock's sustained uptrend over the past year, supported by clinical progress and analyst upgrades

Trend Characteristics: The current trend is characterized as Weak in strength and Weakest in direction, indicating that while the stock remains above key long-term support levels, near-term momentum has faded and the path of least resistance is unclear heading into the earnings event.

At $33.28, STOK is trading above its 5-day moving average of $33.24 and above its 100-day moving average of $33.12, but has slipped below its 10-day ($33.46), 20-day ($34.56), and 50-day ($34.38) moving averages—a pattern consistent with a short-term pullback within a longer-term uptrend. The stock remains well above its 200-day moving average of $28.55, confirming the broader bullish structure is intact.

The technical picture suggests STOK is in a consolidation phase after testing the $40 level in February 2026, with the stock now hovering near the psychologically important $33 level. The 20-day and 50-day moving averages around $34.50 represent immediate overhead resistance, while the 100-day average near $33 and the rising 200-day average at $28.55 provide downside support. Given the weakening short-term momentum signals and the stock's tendency for large post-earnings moves (averaging 6.37% on Day +1), traders should be prepared for a potential breakout above $35 on positive trial news or a retest of the $30-$31 support zone if guidance disappoints or cash burn concerns intensify.

Key technical levels to watch include resistance at the $34.50 area (20-day and 50-day moving averages) and support at the $33 level (100-day moving average). The overall setup is cautiously neutral heading into earnings: while the long-term uptrend remains intact and the stock holds above its 200-day moving average, the recent deterioration in short-term momentum and the stock's position below its 10-day, 20-day, and 50-day moving averages suggest limited technical cushion for disappointment. Investors should be prepared for heightened volatility, with the stock's historical tendency for 6%+ Day +1 moves likely to reassert itself depending on the tone of management's trial enrollment and cash runway commentary.